ZETA|Facility Types & Modalities|Antibody-Drug Conjugates (ADCs)
From to ZETA
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Solutions for Antibody-Drug Conjugate Manufacturing

Meet the challenges of ADC production with our expertise in containment & GMP-compliant facility design.

Antibody-drug conjugates (ADCs) offer powerful, targeted cancer therapies – but manufacturing them involves high-potency compounds and critical safety requirements.
Platform with three FreezeController cabinets
Skid with production vessel, top view

Precision for complex therapeutics. Delivering potency with protection.

ADCs combine monoclonal antibodies with cytotoxic drugs to precisely target diseased cells while sparing healthy tissue. Their manufacture demands rigorous control and containment. ZETA supports ADC manufacturers with closed-system solutions, validated process control, and expertise in high-containment environments (OEB5/OEB6).

Managing the unique challenges of ADCs. Experience drives excellence.

Containment & exposure reduction

High-containment system design (OEB5/OEB6) to safeguard personnel and environment.

High potency API handling

Safe handling and production of potent compounds.

Optimized processing

Precise control of reaction conditions for reliable conjugation.

Product protection

Controlled freezing and packaging to preserve stability throughout the supply chain.

Waste & CIP handling

Robust strategies for cleaning and safe disposal of toxic materials.

From process safety to product stability. Partnering with our customers for progress.

ZETA partners with ADC manufacturers from early planning to full-scale production. We deliver modular, automated systems that align with GMP, safety, and environmental standards. Whether supporting clinical batches or preparing for commercial launch, ZETA ensures your ADC process is efficient, safe, and ready for the demands of tomorrow’s oncology therapies.

3D-image of production plant, including platform with stairs, vessels, piping, cabinets

High-Tech Plant for Antibody-Drug Conjugation

Project realization in just 18 months.

ZETA delivers cutting-edge ADC downstream processing system in record time. Innovative skid-based design and precision engineering enable safe, GMP-compliant production of high-value antibody-drug conjugates in Switzerland.

Your project. Our expertise.
One conversation away.

Johannes Koch
Director Business Line Engineering & Services
Portrait picture of a person wearing a white shirt and a black blazer in front of a light background.
I would like to receive regular information and electronic advertising and agree that my data may be processed and used for this purpose by all companies of the ZETA Group worldwide.
zeta.com is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. By submitting, I agree to the Terms of Use and the Privacy Policy.
>

Please complete the form to receive the requested content.

zeta.com is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. By submitting, I agree to the Terms of Use and the Privacy Policy.

Show content